ANIP
ANI PHARMACEUTICALS INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$72.56
+0.37%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$72.41
From 52W high−23.93%
Volume253202.00
Market cap$1.67B
P/E (TTM)15.0x
P/S (TTM)1.7x
Div yield—
Key dataOct 19, 2026
Open
$72.41
From 52W high
−23.93%
Volume
253202.00
Market cap
$1.67B
ValuationView details →
P/E (Fwd)
7.5x
EV/EBITDA
6.3x
P/E (TTM)
15.0x
RSI (14)
47.5
MomentumView details →
1D Return
+0.37%
YTD Return
−8.35%
SummaryUpdated Jun 1, 2026
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a biopharmaceutical company founded in 2001 and headquartered in Baudette, Minnesota. The company has evolved from a traditional generic drug manufacturer into a specialized pharmaceutical company with a growing focus on rare disease treatments. ANI went public in 2000 and has undergone significant transformation over the past few years, particularly through strategic acquisitions and the successful launch of its rare disease franchise centered around Cortrophin Gel. Today, the company operates as a diversified pharmaceutical manufacturer serving both the generic and specialty drug markets across the United States and Canada.
Similar companies
Latest newsMore news →
ANI PHARMACEUTICALS INC announced the launch of generic Duloxetine Delayed-Release Capsules in 20 mg, 30 mg, and 60 mg strengths.13h agoANI Pharmaceuticals received final FDA approval of its Abbreviated New Drug Application for generic Everolimus Tablets for Oral Suspension 2mg, 3mg and 5mg, a generic version of Afinitor Disperz.27d ago